These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 27070130)
1. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130 [TBL] [Abstract][Full Text] [Related]
2. EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION6ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF-ASSESSMENT MPN-SAF TSS. Shumeiko OO; Poluben LO; Klimuk BT; Rybchenko LA; Neumerzhitskaya LV; Verbilenko RM; Frolov SV; Klymenko SV Probl Radiac Med Radiobiol; 2018 Dec; 23():510-516. PubMed ID: 30582868 [TBL] [Abstract][Full Text] [Related]
3. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Abelsson J; Andréasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P Leuk Lymphoma; 2013 Oct; 54(10):2226-30. PubMed ID: 23398206 [TBL] [Abstract][Full Text] [Related]
4. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137 [TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245 [TBL] [Abstract][Full Text] [Related]
6. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Johansson P; Mesa R; Scherber R; Abelsson J; Samuelsson J; Birgegård G; Andréasson B Leuk Lymphoma; 2012 Mar; 53(3):441-4. PubMed ID: 21883029 [TBL] [Abstract][Full Text] [Related]
7. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms]. Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668 [No Abstract] [Full Text] [Related]
8. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Scherber R; Dueck AC; Johansson P; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Harrison CN; Radia D; Mesa RA Blood; 2011 Jul; 118(2):401-8. PubMed ID: 21536863 [TBL] [Abstract][Full Text] [Related]
9. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182 [TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis. Ümit EG; Baysal M; Kırkızlar HO; Demir AM Turk J Haematol; 2024 Aug; 41(3):175-181. PubMed ID: 38801033 [TBL] [Abstract][Full Text] [Related]
11. Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms. McFarland DC; Polizzi H; Mascarenhas J; Kremyanskaya M; Holland J; Hoffman R J Natl Compr Canc Netw; 2016 Dec; 14(12):1563-1570. PubMed ID: 27956541 [TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064 [TBL] [Abstract][Full Text] [Related]
13. Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research. Eckert R; Huberty J; Gowin K; Mesa R; Marks L Integr Cancer Ther; 2017 Dec; 16(4):439-450. PubMed ID: 27458250 [TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese. Guaraná M; Soares A; Daumas A; Biasoli I; Solza C Hematol Transfus Cell Ther; 2022; 44(3):321-327. PubMed ID: 33483290 [TBL] [Abstract][Full Text] [Related]
15. Assessing disease burden in patients with classic MPNs. Geyer H; Mesa RA Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722 [TBL] [Abstract][Full Text] [Related]
16. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Harrison CN; Koschmieder S; Foltz L; Guglielmelli P; Flindt T; Koehler M; Mathias J; Komatsu N; Boothroyd RN; Spierer A; Perez Ronco J; Taylor-Stokes G; Waller J; Mesa RA Ann Hematol; 2017 Oct; 96(10):1653-1665. PubMed ID: 28780729 [TBL] [Abstract][Full Text] [Related]
17. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients]. Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249 [TBL] [Abstract][Full Text] [Related]
18. The personal impact of living with a myeloproliferative neoplasm. Eppingbroek AAM; Lechner L; Bakker EC; Nijkamp MD; de Witte MA; Bolman CAW Psychooncology; 2024 Apr; 33(4):e6338. PubMed ID: 38610117 [TBL] [Abstract][Full Text] [Related]
19. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Anderson LA; James G; Duncombe AS; Mesa R; Scherber R; Dueck AC; de Vocht F; Clarke M; McMullin MF Am J Hematol; 2015 Oct; 90(10):864-70. PubMed ID: 26113113 [TBL] [Abstract][Full Text] [Related]
20. The Burden of symptoms and Quality of life of Filipino patients with Myeloproliferative neoplasm: A Multicenter Cross-sectional survey. Mesina FZ; Dumagay TE; Alejandria MM Asia Pac J Clin Oncol; 2024 Jul; ():. PubMed ID: 39021300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]